Robert Sambursky

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In
Robert Sambursky
Chief Executive Officer / Lumos Diagnostics Holdings

Mr Sambursky has over 25 years' commercial and medical industry experience in both ophthalmology and infectious disease market segments. Rob co-founded RPS, in 2004, a biotechnology company strategically focused on designing, developing, manufacturing, and marketing novel point-of-care tests for infectious diseases (which merged with Lumos in 2019). With Rob as President and CEO of RPS, the company developed multiple POC diagnostic tests which obtained international regulatory clearances, including U.S. FDA 510(k) clearances with clinical laboratory improvement amendment (CLIA) waiver designations. Rob has served as a consultant and/or acted on the advisory Board of a number of medical companies, including Allergen Inc., NovaBay Pharmaceuticals and Actin BioMed. Rob currently acts as an advisor for Quidel Corporation, a U.S. based manufacturer of diagnostic healthcare products.

Lists and Charts

Total Shareholder Return as at 05/02/26

Rank Company 1 Yr 5 Yr
37th Auris Minerals 563.64% -12.46%
38th EQ Resources 560.88% 35.79%
39th Lumos Diagnostics Holdings 552.11% 0%
40th Paterson Resources 550% 10.2%
41st Benz Mining 541.29% 15.06%
View Full List
1663 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

    Related Information

    Access to our data for Robert Sambursky is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Robert Sambursky is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

    To see the data you will need to Subscribe.

    X